[Skip to Content]
[Skip to Content Landing]
Comment & Response
August 2017

Myeloma Minimal Residual Disease and Surrogacy

Author Affiliations
  • 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland
JAMA Oncol. 2017;3(8):1136. doi:10.1001/jamaoncol.2016.5660

To the Editor We commend Munshi and colleagues1 for their excellent article demonstrating the prognostic value of minimal residual disease (MRD) in multiple myeloma (MM). We agree that these results support MRD as a clinically useful tool for patient management and treatment development. However, we disagree with the authors’ conclusion that these results support the use of MRD as a surrogate end point for long-term clinical outcomes in randomized clinical trials (RCTs).

×